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Aim. To examine the expression of N-methylpurine-DNA glycosylase (MPG) gene and protein in glioma samples with diﬀerent
WHO grades and its association with patients’ survival. Methods. Immunohistochemistry assay, quantitative real-time PCR and
Western blot analysis were carried out to investigate the expression of MPG gene and protein in 128 glioma and 10 non-neoplastic
brain tissues. Results. MPG gene expression level in glioma tissues was signiﬁcantly higher than that in non-neoplastic brain tissues
(P<0.001). Immunohistochemistry also showed that MPG protein was over-expressed in glioma tissues, which was consistent
with the resutls of Western blot analysis. Additionally, the expression levels of MPG gene and protein both increase from grade I to
gradeIVgliomaaccordingtotheresultsofreal-timePCR,immunohistochemistryandwesternblotanalysis.Moreover,thesurvival
rate of MPG-positive patients was signiﬁcantly lower than that of MPG-negative patients (P<0.001). We further conﬁrmed that
the over-expression of MPG was a signiﬁcant and independent prognostic indicator in glioma by multivariate analysis (P<0.001).
Conclusions. Our data showed the over-expression of MPG gene and protein in human gliomas, and also suggested for the ﬁrst
time that MPG be an unfavorable independent prognostic indicator for glioma patients.
1.Introduction
Human gliomas represent 50% to 60% of all intracranial
tumors [1]. According to the World Health Organization
(WHO) guidelines [2], gliomas are histologically classiﬁed
into four grades: pilocytic astrocytoma (grade I), low-grade
diﬀuseastrocytoma(gradeII),anaplasticastrocytoma(grade
III), and glioblastoma multiforme (GBM, grade IV). Both
diagnostic technologies and therapeutic strategies have been
greatly advanced, but glioma remains one of the deadliest
humancancers.The5-yearsurvivalratesoflow-grade(grade
I∼II) and high-grade (grade III∼I V )g l i o m ap a t i e n t si n
China are 75.4% and 18.2%, respectively [3]. Especially,
the median survival time for patients with GBM is still
only 12 months [4]. Indeed, early diagnosis and prolonging
survival in glioma patients remains a great challenge for
clinicians in the ﬁeld of neurooncology. There have been
several prognostic factors for glioma patients, such as age,
preoperative duration of symptoms, Karnofsky performance
status (KPS) score, histologic grade, tumor necrosis, surgical
resection extent, use of postoperative radiation therapy,
and, probably, adjuvant chemotherapy [5]. However, these
clinical parameters cannot completely account for the
observed variation in survival because of the heterogeneity
of glioma patients [6]. Thus, there is an urgent need to
further investigate the molecular mechanisms of glioma and
to identify the eﬀective prognostic indicators for survival
prediction.The DNA-base excision repair (BER) pathway is
responsible for the repair of exogenous and endogenous
alkylating and oxidative DNA damage, which may lead
to carcinogenesis, cell death, and aging if left unrepaired
[7]. The schematic diagram of BER pathway is shown as2 Journal of Biomedicine and Biotechnology
Figure 1. This pathway involves the recognition and removal
of damaged bases by a DNA glycosylase, followed by incision
of the resulting abasic (AP) site by AP endonuclease, DNA
synthesis by polymerase, and strand ligation by DNA ligase
[8]. Thus, the BER pathway is an important candidate for
intervention into the cellular responses to DNA change.
N-methylpurine-DNA glycosylase (MPG) as a DNA repair
enzyme is a main component in the BER pathway [9]. In
previous study aimed at understanding the signiﬁcance of
initiating lesions removed by the BER pathway, Kaina et
al. [10] identiﬁed the over-expression of the human MPG
in Chinese hamster ovary cells. In the N-alkylpurine repair
process, MPG is responsible for the glycolytic removal of
the modiﬁed base, which leads to the formation of apurinic
sites. Although N-alkylpurines have not been found to be
directly mutagenic, apurinic sites left by this repair process
can block replication and lead to mutation [11]. MPG
also participates in the repair of 8-hydroxyguanine and
hypoxanthine [12]. Because of the potential role of DNA
base lesions in mutagenesis and carcinogenesis, a number of
studies have been performed to investigate the association of
MPG with various human cancers. Cerda et al. (1998) [13]
detected the increased MPG gene and protein expression in
the breast cancer cells versus normal breast epithelial cells
by northern analysis, southern blots, immunoﬂuorescence,
immunohistochemistry, and western blot analysis. In 2001,
Sohn et al. [14] reported that the expression of MPG was
increased in high-risk HPV-infected cervical neoplasias and
the intracellular distribution of MPG protein was altered,
suggesting a role of MPG in carcinogenesis. In an eﬀort to
improve the eﬃcacy of cancer chemotherapy by intervening
into the cellular responses to chemotherapeutic change,
many researchers have been interested in the eﬀects of
MPG in tumor sensitivity to the clinical chemotherapeutic
agents. As their results, MPG-overexpressing ovarian cancer
[15], osteosarcoma [16], and breast cancer [17] cells are
signiﬁcantly more sensitive to the clinical chemotherapeutic
agents, suggesting that the overexpression of MPG may be
a possible gene therapy approach to sensitize tumor cells to
the cell-killing eﬀects of chemotherapeutic alkylating agents.
The biological mechanism behind the increase of sensitivity
to the chemotherapeutic agents in MPG overexpressing cell
lines may be that the balance between glycosylase activity,
leading to apurinic sites and formation of strand breaks, and
subsequent excision repair processes may play an important
role in determining cellular cytotoxicity and resistance to
alkylating agents [13].
Of our interests, we focus on the involvement of MPG in
human gliomas. Recent study has demonstrated that MPG
mRNA expression was higher in astrocytic tumor tissues
than in brain tissues adjacent to tumor, and MPG protein
localization in immunohistochemical study was detected
only in the nucleus of all tumor tissues, suggesting an MPG’s
role in human astrocytic tumors and raise the possibility that
the altered MPG expression and intracellular localization
could be associated with astrocytic tumorigenesis [18]. Tang
et al. [19] further demonstrated that MPG overexpression,
together with the inhibition of BER, could sensitize glioma
cells to the alkylating agent. However, little is known
about the expression level of MPG in human gliomas with
diﬀerent clinical grades and its prognostic signiﬁcance. To
address this problem, we used quantitative real-time PCR,
immunohistochemistry assay, and western blot analysis to
investigate the expression pattern of MPG gene and protein
in glioma specimens and normal control brain tissues. Next,
we analyzed the relationship between MPG expression and
the glioma stage as well as the survival of patients.
2.MaterialsandMethods
2.1. Patients and Tissue Samples. This study was approved by
the Research Ethics Committee of the Institute for functional
neurosurgery P.L.A, TangDu Hospital, Fourth Military Med-
ical University, Xi’an, P.R. China. Written informed consent
was obtained from all of the patients. All specimens were
handled and made anonymous according to the ethical and
legal standards.
A total of 128 formalin-ﬁxed, paraﬃn-embedded spec-
imens of gliomas resected between 2000 and 2010 were
retrieved from the archives of the Pathology Department
of Tangdu Hospital, Fourth Military Medical University,
P.R. China. All the slides were reevaluated according to
WHOclassiﬁcations[2]bytwopathologists,withdiﬀerences
resolved by careful discussion. A total of 76 males and 52
females (1.46:1) were enrolled in this study, and the median
age was 42 years (range, 12–71). Thirty-two of the 128
gliomas were classiﬁed as low-grade [18 pilocytic astrocy-
tomas (WHO I) and 14 diﬀuse astrocytomas (WHO II)],
and 96 were classiﬁed as high-grade gliomas [38 anaplasia
astrocytomas (WHO III), and 58 primary glioblastomas
(WHO IV)]. None of the patients had received chemother-
apy or radiotherapy prior to surgery. The clinicopathological
features, and the treatment strategies of all the patients were
indicated in Table 1.P a r a ﬃn and snap-frozen sections of
nonneoplastic brain tissues from 10 patients with intractable
epilepsy were also included as controls. Five-year followup
was performed, and all patients had complete followup until
death. Overall survival time was calculated from the date
of the initial surgical operation to death. Patients, who
died of diseases not directly related to their gliomas or
due to unexpected events, were excluded from this study.
In addition, 20 glioma specimens [5 pilocytic astrocytomas
(WHO I), 3 diﬀuse astrocytomas (WHO II), 3 anaplasia
astrocytomas (WHO III), and 9 primary glioblastomas
(WHO IV)] were snap-frozen in liquid nitrogen and stored
at −80◦C following surgery for mRNA and protein isolation.
2.2. Quantitative Real-Time PCR. Total RNA puriﬁed from
all 20 glioma tissues and 10 control brain tissues was
prepared and reverse transcribed. Real-time monitoring of
polymerase chain reactions (PCRs) was performed using
the ABI 7900HT (Idaho Technology, Idaho Falls, ID, USA).
cDNA was synthesized using random primers and Oligo
18dT and Superscript II Reverse Transcriptase (Invitrogen).
Gene expression was determined using the SYBR green I
dye(Biogene),whichbindspreferentiallytodouble-stranded
DNA, and 10ng of template. Fluorescence signals, which areJournal of Biomedicine and Biotechnology 3
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Figure 1: The schematic diagram of base excision repair (BER) pathway for DNA repair throughout the cell cycle. BER is important for
removing damaged bases. BER is initiated by DNA glycosylases (e.g., MPG), which recognize and remove speciﬁc damaged or inappropriate
bases, forming AP sites. These are then cleaved by an AP endonuclease. The resulting single-strand break can then be processed by either
short-patch or long-patch BER.
proportional to the concentration of the PCR product, are
measured at the end of each cycle and immediately displayed
on a computer screen, permitting real-time monitoring of
the PCR. The reaction is characterized by the point during
cycling when ampliﬁcation of PCR products is ﬁrst detected,
rather than the amount of PCR product accumulated after a
ﬁxed number of cycles. The higher the starting quantity of
the template, the earlier a signiﬁcant increase in ﬂuorescence
is observed. The threshold cycle is deﬁned as the fractional
cycle number at which ﬂuorescence passes a ﬁxed threshold
above the baseline. The primers 5 -GTC CTA GTC CGG
CGA CTT CC-3  and 5 -CTT GTC TGG GCA GGC CCT
TTG C-3  were used to amplify 603-bp transcripts of MPG,
and the primers 5 -GGT GGC TTT TAG GAT GGC AAG−3 
and 5 - A C TG G AA C GG T GA A GG T GA C AG −3  were
used to amplify 161-bp transcripts of β-actin. All primers
weresynthesized by Sangon Co. (Shanghai, China). The PCR
proﬁle consisted of an initial melting step of 1min at 94◦C,
followed by 38 cycles of 15s at 94◦C, 15s at 56◦C, and 45s at
72◦C, and a ﬁnal elongation step of 10min at 72◦C.
Fluorescence data were converted into cycle threshold
measurements using the SDS system software and exported
to Microsoft Excel. MPG mRNA levels were compared to β-
actin. Thermal dissociation plots were examined for biphasic
melting curves, indicative of whether primer dimers or
other nonspeciﬁc products could be contributing to the
ampliﬁcation signal.
2.3. Western Blot Analysis. Twenty glioma tissues and 10
control brain tissues were homogenized in lysis buﬀer
[PBS, 1% nonidet P-40 (NP-40), 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate (SDS), 100ug/mL aprotinin,
100μg/mL phenylmethylsulfonyl ﬂuoride (PMSF), Sodium
orthovanadate] at 4◦C throughout all procedures, and
sonicated for 70s, then add 300μgP M S Fp e rg r a mo ft i s s u e
and incubate on ice for 30min, followed by centrifugation
at 15,000rpm for 20min at 4◦C. The protein content
was determined according to Bradford’s method [20], with
bovine serum albumin used as a standard. Protein samples
(30μg) were boiled with 2 × sample buﬀer containing
5% β-mercaptoethanol for 5min, separated by size on 15%
polyacrylamide gel under SDS denaturing conditions, and
transferred to a nitrocellulose membrane at 90V for 2h.
The nitrocellulose membranes were stained with ponceau
S to assess the eﬃciency of transfer. Nonspeciﬁc binding
was blocked by incubation in block buﬀer (5% nonfat
dry milk, 0.05% Tween-20, 1 × tris-Cl-buﬀered saline)
overnight at 4◦C, The membranes were hybridized with a
mouse monoclonal antibody to MPG (ab55461; Abcam),
then incubated with a horseradish peroxidase-labeled goat
anti-mouse IgG (1:500). The bound secondary antibody
was detected by enhanced chemiluminescence (Amersham
Life Science, Little Chalfont, UK). Housekeeping protein β-
actin was used as a loading control. Positive immunoreactive
bands were quantiﬁed densitometrically (Leica Q500IW
image analysis system) and expressed as ratio of MPG to β-
actin in optical density units.
2.4. Immunohistochemistry Assay. Immunohistochemical as-
say was performed using the conventional immunoperoxi-
dase technique according to the protocol of the Department
of Neurosurgery, Institute for functional neurosurgery P.L.A,
TangDu Hospital, Fourth Military Medical University, Xi’an,
P.R. China. Brieﬂy, following peroxidase blocking with 0.3%4 Journal of Biomedicine and Biotechnology
Table 1: MPG expression in human glioma and nonneoplastic brain tissues with diﬀerent clinical-pathological features.
Clinicopathological features No. of cases MPG (n,% )
P
− + ++ +++
Human glioma tissues
WHO grade
I 18 14 (77.8) 4 (22.2) 0 0
0.002 II 14 8 (57.1) 4 (28.6) 2 (14.3) 0
III 38 4 (10.5) 19 (50.0) 13 (34.2) 2 (5.3)
IV 58 0 0 15 (25.9) 43(74.1)
Age
<55 52 7 (13.5) 11 (21.2) 14 (26.9) 20 (38.5) NS
≥55 76 19 (25.0) 16 (21.1) 16 (21.1) 25 (32.9)
Gender
Male 76 19 (25.0) 19 (25.0) 15 (19.7) 23 (30.2) NS
Female 52 7 (13.5) 8 (15.4) 15 (28.8) 22 (42.3)
KPS
<80 78 6 (7.7) 15 (19.2) 22 (28.2) 35 (44.9) 0.01
≥80 50 20 (40.0) 12 (24.0) 8 (16.0) 10 (20.0)
Surgery
Gross total resection 98 18 (18.4) 19 (19.4) 28 (28.6) 33 (33.7)
NS Partial resection 24 6 (25.0) 6 (25.0) 1 (4.2) 11 (45.8)
Biopsy 6 2 (33.3) 2 (33.3) 1 (16.7) 1 (16.7)
Nonneoplastic brain tissues
Age
<55 4 3 (75.0) 1 (25.0) 0 0 NS
≥55 6 5 (83.3) 1 (16.7) 0 0
Gender
Male 6 5 (83.3) 1 (16.7) 0 0 NS
Female 4 3 (75.0) 1 (25.0) 0 0
H2O2/methanol for 30min, specimens were blocked with
phosphate-buﬀered saline (PBS) containing 5% normal
horse serum (Vector Laboratories Inc., Burlingame, CA,
USA). All incubations with a mouse monoclonal antibody to
MPG (ab55461; Abcam) at 1:500 dilution were carried out
overnight at 4◦C. Then the specimens were brieﬂy washed in
PBSandincubatedatroomtemperaturewiththeanti-mouse
antibody and avidin-biotin peroxidase (Vector Laboratories
Inc., Burlingame, CA, USA). The specimens were then
washed in PBS and color developed by diaminobenzidine
solution (Dako Corporation, Carpinteria, CA, USA). After
washing with water, specimens were counterstained with
Meyer’s hematoxylin (Sigma Chemical Co., St Louis, MO,
USA). Nonneoplastic brain tissues were used as control
tissues, and nonimmune IgG was also used as negative
control antibody for immunohistochemical staining.
Stained sections were observed under a microscope.
Immunostaining was scored by two independent experi-
enced pathologists, who were blinded to the clinicopatho-
logic parameters and clinical outcomes of the patients. An
immunoreactivity score system was applied as described
previously [17]. The extensional standard was (1) the
number of positively stained cells <5% scored 0, 6–25%
scored 1, 26–50% scored 2, 51–75% scored 3, >75% scored
4; (2) intensity of stain: colorless scored 0, pallide-ﬂavens
scored 1, yellow scored 2, brown scored 3. Multiply (1) and
(2). The staining score was stratiﬁed as − (0 score, absent),
+( 1 – 4s c o r e ,w e a k ) ,+ +( 5 – 8s c o r e ,m o d e r a t e ) ,a n d+ + +( 9 –
12 score, strong) according to the proportion and intensity
of positively stained cancer cells. Specimens were rescored if
diﬀerence of scores from two pathologists was >3.
2.5. Statistical Analysis. All computations were carried out
using the software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA). The rank sum test was used to analyze the
ranked data. The measurement data were analyzed by one-
way ANOVA. Randomized block design ANOVA was used
to analyze the statistical diﬀerence among diﬀerent tissue
types. In the analysis of glioma morbidity for all patients,
we used the Kaplan-Meier estimator and univariate Cox
regressionanalysistoassessthemarginaleﬀectofeachfactor.
The diﬀerences between groups were tested by log-rank
analyses. The joint eﬀect of diﬀerent factors was assessed
using multivariate Cox regression. A Spearman’s analysis was
carried out to analyze the correlation between MPG mRNAJournal of Biomedicine and Biotechnology 5
and protein expression levels. Diﬀerences were considered
statistically signiﬁcant when P was less than 0.05.
3. Results
3.1. Quantitative Analysis of MPG Gene Expression Based
on WHO Grades in Gliomas. The gene expression of MPG
normalized to β-actin in 20 glioma and 10 control brain
tissues was detected by real-time PCR. As shown in Figure 2,
the expression levels of MPG gene in human glioma tissues
wereconspicuouslyhigherthanthoseincontrolbraintissues
(P<0.001). Additionally, we also analyzed the expression of
MPG gene based on WHO grade. Interestingly, MPG gene
expression increased with the advancement of WHO grades
from I to IV (P<0.001).
3.2. Quantitative Analysis of MPG Protein Expression Based
on WHO Grades in Gliomas. The protein expression of MPG
normalized to β-actin in 20 glioma and 10 control brain
tissues was also detected by Western blot analysis. As the
results, the expression levels of MPG protein tended to
increase from the glioma to the normal tissue (Figures 3(a)
and 3(c)). We also investigated whether the expression of
MPG correlated with the WHO grade. MPG expression was
highest in grade IV and lowest in grade I (Figures 3(b)
and 3(c)), indicating a close correlation of MPG protein
expression with WHO grade. There was a signiﬁcant positive
correlation between the expression of MPG gene and protein
expression levels from the same glioma tissues (rs = 0.82,
P<0.001).
3.3. MPG Protein Expression in Glioma Tissues by Immuno-
histochemistry Assay and Survival Analysis. The expression
and the subcellular localization of MPG protein in 10
nonneoplastic brain and 128 glioma tissues were detected
by immunohistochemistry assay. As shown in Figure 4, the
positive staining for MPG was mainly observed in the nuclei
of tumor cells in glioma tissues, which was consistent with
the previous study of wang et al. [16]. The representative
photographs were shown in Figures 4(a) and 4(b). Among
the glioma specimens, 102 (79.7%) glioma specimens were
positively stained for MPG, whereas its immunoreactivities
in nonneoplastic brain sections ranged from undetectable
to low (Figure 4(c)). Additionally, the immunostaining of
MPG in nonneoplastic brain tissues is below detection levels
of both real-time PCR and Western blot. According to the
statistical analysis, the expression level of MPG protein in
glioma tissues was signiﬁcantly higher (P<0.001) than that
in nonneoplastic brain tissues, which was consistent with the
results of Western blot analysis.
In addition, MPG expression was not signiﬁcantly
aﬀectedbythegenderandage(bothP>0.05)ofthepatients.
In contrast, the MPG expression was the closely correlated
with WHO grade, as well as KPS. The expression levels of
MPG protein in glioma tissues with higher WHO grade
(Table 1; P = 0.002) and lower KPS (Table 1; P = 0.01) were
signiﬁcantly higher than those with lower WHO grade and
higher KPS.
NC aNC a
603 bp
161 bp
MPG
β-actin
(a)
603 bp
161 bp
MPG
β-actin
I II III IV
(b)
0
1
2
3
R
a
t
i
o
 
o
f
 
M
P
G
 
m
R
N
A
t
o
β
-
a
c
t
i
n
 
m
R
N
A
∗
Ca IV Ca III Ca II Ca IN
∗∗
∗∗
∗∗
(c)
Figure 2: Expression of MPG gene in glioma and nonneoplastic
brain tissues by quantitative real-time PCR analysis. (a) MPG gene
expression levels in glioma (lanes 2 and 4) and nonneoplastic brain
tissues (lanes 1 and 3). (b) MPG gene expression levels in glioma
with diﬀerent WHO grades. Lanes 1 to 4: MPG gene expression
in glioma tissues with WHO grade I, II, III, and IV, respectively.
(c) MPG gene expression levels in nonneoplastic brain tissues and
glioma with diﬀerent WHO grades. “N” refers to nonneoplastic
brain tissues; “Ca” refers to glioma tissues; “Ca I”∼“Ca IV” refer
to glioma tissues with WHO grade I∼IV. β-actin was used as an
internal control for quantitative real-time PCR analysis. Values
are means ±SD. ∗P<0.05, comparison with nonneoplastic brain
tissues; ∗∗P<0.001, comparison with nonneoplastic brain tissues.
Moreover, we reviewed clinical information of these
MPG-positive or -negative glioma patients. During the
follow-up period, 100 of the 128 glioma patients (78.1%)
had died (24 from the MPG-negative group and 76 from
the MPG-positive group). As determined by the log-rank
test, the survival rate of patients with positive MPG staining
was lower than those without MPG staining (P<0.001;
Figure 5(a)). The median survival time of patients with
negative expression of MPG could not be estimated by
statistical analysis because all patients survived better than
the overall median level, and those patients with strong
positive (+++), moderate positive (++), and weak positive6 Journal of Biomedicine and Biotechnology
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Figure 3: Expression of MPG protein in glioma and nonneoplastic
brain tissues by Western blot analysis. (a) MPG protein expres-
sion levels in glioma and nonneoplastic brain tissues. (b) MPG
expression levels in glioma with diﬀerent WHO grades. (c) MPG
expression levels in nonneoplastic brain tissues and glioma with
diﬀerent WHO grades. “N” refers to nonneoplastic brain tissues;
“Ca”referstogliomatissues;“Ca I”∼“Ca IV”refertogliomatissues
with WHO grade I∼IV. β-actin was used as a control for equal
protein loading. Values are means ±SD. ∗P<0.05, comparison
with nonneoplastic brain tissues; ∗∗P<0.001, comparison with
nonneoplastic brain tissues.
(+) of MPG were 9.1 ± 1.5 months, 12.3 ± 1.1 months, and
22.6 ±2.2 months (log-rank test: P<0.001).
Furthermore, Figure 5(b) shows the postoperative sur-
vival curve of patients with glioma and MPG expression
after adjusting for age, gender, WHO grade, and KPS. By
multivariate analysis (Table 2), the loss of MPG expression
was a signiﬁcant (P<0.001) and independent prognostic
indicator for patients with glioma besides age, WHO grade
and KPS. The Cox-proportional hazards model showed
that MPG over-expression was associated with poor overall
survival.
4. Discussion
Because of the dismal survival in the patients with glioma,
especially in GBM patients, there is an urgent need to ﬁnd
Table 2: Cox-multivariate analysis.
Parameter Risk ratio 95% conﬁdence
interval P
Age 0.89 0.58–1.65 0.71
Gender 1.02 0.66–1.83 0.33
KPS 1.99 1.28–2.95 0.06
WHO grade 3.63 2.28–7.59 0.03
Extent of resection 1.29 0.89–2.13 0.11
MPG expression 6.75 2.06–15.38 <0.001
novel speciﬁc and eﬀective prognostic markers in order
to apply individualized treatments to speciﬁcally target
the pathophysiologic and molecular properties of glioma
patients. In the current study, we investigated the expression
of MPG in 128 cases of human glioma and compared the
expression with tumor grade and survival rates of patients.
Our data demonstrated that MPG gene and protein were
both increased in glioma compared to nonneoplastic brain
tissue. We found an increased trend of both MPG protein
level and gene level from WHO grade I to WHO grade IV
glioma. These results suggest that the transcriptional and
translational activation of human MPG might participate in
the tumorigenesis and progression of glioma.
DNA in all somatic and germ cells in the body are
continuously exposed to exogenous and endogenous alky-
lating and oxidative agents that result in damage to DNA.
If DNA damage was not repaired, it may lead to genetic
mutation, chromosome aberration, aging, and carcinogen-
esis. Thus, DNA repair is essential for survival of life. The
lack of precise DNA repair activities may lead to defective
embryogenesis, tissue-speciﬁc dysfunction, hypersensitivity
to DNA-damaging agents, premature senescence, genetic
instability,andelevatedcancerrates.TheBERpathwayisone
of the predominant pathways for DNA repair. The repair of
DNA bases damaged by alkylation is initiated in mammalian
cells by MPG, as an alkyladenine DNA glycosylase [21].
The majority of repair that is initiated by MPG occurs via
short-patch BER, a mechanism whereby only one nucleotide
is replaced. MPG has broad speciﬁcity for a number of
damaged DNA bases. The majority of base damage induced
by methylation is removed by MPG, including the principal
adducts 3-meA and 7-meG [22]. It has been reported that
the expression of MPG could be induced by viral damage
and a variety of DNA-damaging agents. For example, the
increased expression of MPG gene was studied in breast
cancer, cervical neoplasia, and thymic carcinoma in SV
40 T-antigen-expressing transgenic mice [23]. As previous
investigation,mammaliancellsactivelyregulatedDNArepair
enzymes and genes during cell proliferation. DNA repair
enzymes are expressed in the cell cycle in a deﬁned temporal
pattern relative to the induction of DNA replication. In brain
cells that are not undergoing DNA replication, DNA repair
is maintaining nucleotide sequences of genomic DNA over
time. Kim et al. [24] indicated that MPG expression in the
brain was relative high in 1 week after birth, and the levelJournal of Biomedicine and Biotechnology 7
(a) (b) (c)
Figure 4: Immunohistochemical staining of MPG protein in tumor cells of GBM (a) and astrocytoma (b) (original magniﬁcation × 200).
Staining for this antigen is described in Materials and Methods. Positive staining of MPG is seen in the nuclei of tumors cells and is more
abundant in the high- (a) than the low-grade (b) tumors. Negative expression of MPG (c) was observed in nonneoplastic brain tissues.
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Figure 5: Postoperative survival curves for patterns of patients with glioma and MPG expression. (a) Kaplan-Meier postoperative survival
curve for patterns of patients with glioma and MPG expression. (b) Cox-proportional hazards model after adjusting for age, gender, and
grade. MPG might be an independent predictor of survival, without consideration of age, gender or grade. “a” refers to MPG-negative
expression group; “b” refers to MPG-weak positive (+) expression group; “c” refers to MPG-moderate positive (++) expression group; “d”
refers to MPG strong positive (+++) expression group.
remained low in day 400 mature adults, suggesting that
brain tissue is terminally diﬀerentiated and nonproliferating
tissues.
It has been demonstrated that DNA repair enzymes play
an important role in the carcinogenesis of several cancers. Of
our interests, MPG was overexpressed in breast cancer up to
24-fold as compared to normal primary breast epithelium,
suggesting the role of MPG in breast carcinogenesis [12]. In
astrocytomas, Kim et al. [18] in 2003 reported that MPG
mRNA level was signiﬁcantly higher than that in tumor-
adjacent brain tissues. With the similar results, we in this
study also found the upregulation of MPG protein and gene
in glioma tissues. Additionally, we provide evidence that
MPG protein is found in nuclear localization of the glioma
tissues, which was consistent with the results of Kim et al.
[18]. The nuclear localization of MPG in tumor cells of
glioma tissues may be suggestive of a role of MPG in the
regulation of cell division and cell cycle. Furthermore, the
most important ﬁnding of this study was the correlation
of MPG expression and survival rates of patients. Our data
indicated that nearly 80% of glioma cases showed positive
staining for MPG. The survival rate of patients with positive
MPG staining was lower than those without. Kaplan-Meier
and multivariate analysis both showed a signiﬁcantly worse
o v e r a l ls u r v i v a lf o rp a t i e n t sw h o s et u m o r sh a dh i g hM P G
levels, indicating that high MPG protein level is a marker
of poor prognosis for patients with gliomas. This is the ﬁrst
investigation to demonstrate the prognostic value of MPG in
human cancers. Further validations with larger sample size
and diﬀerent methodologies are warranted.
In conclusion, our data showed the over-expression of
MPG gene and protein in human gliomas and also suggested
for the ﬁrst time that MPG be an unfavorable independent
prognostic indicator for glioma patients.8 Journal of Biomedicine and Biotechnology
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